BE678807A - - Google Patents

Info

Publication number
BE678807A
BE678807A BE678807DA BE678807A BE 678807 A BE678807 A BE 678807A BE 678807D A BE678807D A BE 678807DA BE 678807 A BE678807 A BE 678807A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26260578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE678807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB34989/62A external-priority patent/GB1013907A/en
Application filed filed Critical
Publication of BE678807A publication Critical patent/BE678807A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/64—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring
    • C07C37/66—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring by conversion of hydroxy groups to O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE678807D 1962-09-13 1966-03-31 BE678807A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB34989/62A GB1013907A (en) 1962-09-13 1962-09-13 Alkene derivatives
GB30755/65A GB1064629A (en) 1962-09-13 1965-07-20 Alkene derivatives

Publications (1)

Publication Number Publication Date
BE678807A true BE678807A (en:Method) 1966-09-30

Family

ID=26260578

Family Applications (2)

Application Number Title Priority Date Filing Date
BE637389D BE637389A (en:Method) 1962-09-13
BE678807D BE678807A (en:Method) 1962-09-13 1966-03-31

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE637389D BE637389A (en:Method) 1962-09-13

Country Status (8)

Country Link
US (1) US4536516A (en:Method)
BE (2) BE678807A (en:Method)
BR (2) BR6352734D0 (en:Method)
CH (3) CH441286A (en:Method)
DE (1) DE1568834A1 (en:Method)
DK (3) DK118655B (en:Method)
FR (1) FR1502607A (en:Method)
GB (1) GB1064629A (en:Method)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401132A1 (fr) * 1977-08-22 1979-03-23 Ici Ltd Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant
FR2463121A1 (fr) * 1979-08-15 1981-02-20 Egyt Gyogyszervegyeszeti Gyar Derives du 1,1,2-triphenylpropane et du 1,1,2-triphenylpropene, procede de preparation de ces derives et compositions pharmaceutiques contenant ces nouveaux composes
EP0659420A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating sexual precocity
EP0659421A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating menstrual symptoms
EP0659413A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibiting CNS problems in postmenopausal women.
EP0659415A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibition of vasomotor symptoms and treatment of psychological complaints related to post-menopausal syndrome.

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (en:Method) * 1962-09-13
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
EP0127128B1 (en) * 1983-05-24 1987-02-25 Bristol-Myers Company Process for the conversion of the e isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen hcl
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4806685A (en) * 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5354861A (en) * 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
GB9326255D0 (en) * 1993-12-23 1994-02-23 Roussel Lab Ltd Medical device for the prevention and treatment of cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
TW398975B (en) 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP0883587A1 (en) 1996-01-20 1998-12-16 Bradford University Tamoxifen and analogues thereof
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
EP0981337A4 (en) * 1997-02-09 2003-03-12 Pharmos Corp IMPROVED ANTI-ANGIOGENIC ACTIVITY OF CONSTANTLY LOADED DERIVATIVES OF STEROID HORMONES
US6083990A (en) 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
WO1998037892A1 (en) * 1997-02-27 1998-09-03 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
GB9715479D0 (en) * 1997-07-23 1997-10-01 Univ Bradford Tamoxifen and analogues thereof
PL338555A1 (en) 1997-08-15 2000-11-06 Univ Duke Method of preventing or treating oestrogen-dependent diseases and disorders
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
JP4842514B2 (ja) * 2002-03-20 2011-12-21 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物
EP1545479B1 (en) * 2002-07-30 2010-10-27 Karykion Inc. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
BRPI0606455A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
WO2007011962A2 (en) 2005-07-18 2007-01-25 Bipar Sciences, Inc. Treatment of cancer
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2551690T3 (es) 2006-05-22 2015-11-23 Hormos Medical Ltd. Método de tratamiento de la prostatitis crónica no bacteriana con moduladores selectivos del receptor de estrógeno o inhibidores de aromatasa
KR20090029237A (ko) 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PE20090510A1 (es) 2007-08-03 2009-05-22 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
CN101896174B (zh) 2007-10-16 2012-10-31 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2013116293A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
EP2819676B1 (en) 2012-02-29 2018-05-30 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EP2822955B1 (en) 2012-03-05 2017-07-26 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CN103992234B (zh) * 2014-06-11 2016-05-18 扬子江药业集团江苏海慈生物药业有限公司 一种枸橼酸他莫昔芬e异构体的制备方法
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
WO2017120204A2 (en) 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
EP3493794A4 (en) 2016-08-04 2020-05-06 University of Iowa Research Foundation USE OF SWELL1 INHIBITORS AND MODULATORS FOR TREATING TYPE 2 DIABETES AND ADIPOSITAS
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
KR20200138714A (ko) 2018-02-21 2020-12-10 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 및 글루타메이트성 작용제를 사용한 병용 요법
WO2020252018A1 (en) * 2019-06-10 2020-12-17 University Of Iowa Research Foundation Swell 1 modulators for treatment of non-alcoholic fatty liver disease, immune deficiencies, male infertility and vascular diseases
CN114133334B (zh) * 2021-11-09 2024-07-19 北京京丰制药(山东)有限公司 枸橼酸他莫昔芬的工业化制备工艺
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4311546A1 (en) 2022-07-26 2024-01-31 Dynacure Combination therapy for myopathies
WO2024254189A1 (en) 2023-06-06 2024-12-12 Daré Bioscience, Inc. Compositions and methods for treating vulvar and vaginal atrophy (vva)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
BE637389A (en:Method) * 1962-09-13
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401132A1 (fr) * 1977-08-22 1979-03-23 Ici Ltd Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant
FR2463121A1 (fr) * 1979-08-15 1981-02-20 Egyt Gyogyszervegyeszeti Gyar Derives du 1,1,2-triphenylpropane et du 1,1,2-triphenylpropene, procede de preparation de ces derives et compositions pharmaceutiques contenant ces nouveaux composes
EP0659420A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating sexual precocity
EP0659421A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating menstrual symptoms
EP0659413A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibiting CNS problems in postmenopausal women.
EP0659415A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibition of vasomotor symptoms and treatment of psychological complaints related to post-menopausal syndrome.

Also Published As

Publication number Publication date
DE1568834A1 (de) 1970-11-26
CH441286A (de) 1967-08-15
DK127777B (da) 1974-01-07
DK118655B (da) 1970-09-21
FR1502607A (fr) 1967-11-24
DK117953B (da) 1970-06-22
CH538447A (de) 1973-06-30
GB1064629A (en) 1967-04-05
DE1468088A1 (de) 1969-07-31
CH446289A (de) 1967-11-15
BE637389A (en:Method)
US4536516A (en) 1985-08-20
BR6352734D0 (pt) 1973-09-18
BR6678265D0 (pt) 1973-09-18

Similar Documents

Publication Publication Date Title
BE616548R (en:Method)
BE615521A (en:Method)
BE615804A (en:Method)
BE380301A (en:Method)
BE489310A (en:Method)
BE538252A (en:Method)
BE538831A (en:Method)
BE541929A (en:Method)
BE553896A (en:Method)
BE559145A (en:Method)
BE586180A (en:Method)
BE592434A (en:Method)
BE599783A (en:Method)
BE604335A (en:Method)
BE608197A (en:Method)
BE609543A (en:Method)
BE612190A (en:Method)
BE612311A (en:Method)
AU269855A (en:Method)
BE612847A (en:Method)
BE612926A (en:Method)
BE613108A (en:Method)
BE613190A (en:Method)
BE613298A (en:Method)
BE613319A (en:Method)